Alnylam Pharmaceuticals annual total assets
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Alnylam Pharmaceuticals Total Assets Growth & History (ALNY)
Alnylam Pharmaceuticals's total assets was $4.97B for fiscal 2025.
View full Alnylam Pharmaceuticals company overviewAlnylam Pharmaceuticals annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.97B | $726.3M | +17.13% |
| 2024 | 2024-12-31 | $4.24B | $410.1M | +10.71% |
| 2023 | 2023-12-31 | $3.83B | $283.5M | +7.99% |
| 2022 | 2022-12-31 | $3.55B | −$96.9M | −2.66% |
| 2021 | 2021-12-31 | $3.64B | $236.2M | +6.93% |
| 2020 | 2020-12-31 | $3.41B | $1.01B | +42.25% |
| 2019 | 2019-12-31 | $2.40B | $820.3M | +52.09% |
| 2018 | 2018-12-31 | $1.57B | −$419.9M | −21.05% |
| 2017 | 2017-12-31 | $1.99B | $731.9M | +57.96% |
| 2016 | 2016-12-31 | $1.26B | −$123.7M | −8.92% |
| 2015 | 2015-12-31 | $1.39B | $306.9M | +28.43% |
| 2014 | 2014-12-31 | $1.08B | $659.1M | +156.72% |
| 2013 | 2013-12-31 | $420.5M | $133.0M | +46.26% |
| 2012 | 2012-12-31 | $287.5M | $5.6M | +1.99% |
| 2011 | 2011-12-31 | $281.9M | −$111.3M | −28.31% |
| 2010 | 2010-12-31 | $393.3M | −$88.1M | −18.31% |
| 2009 | 2009-12-31 | $481.4M | — | — |
Alnylam Pharmaceuticals quarterly total assets
Q4.09
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.56B | $992.8M | +21.74% |
| Q1 2026 | 2026-03-31 | $5.13B | $915.7M | +21.73% |
| Q4 2025 | 2025-12-31 | $4.97B | $726.3M | +17.13% |
| Q3 2025 | 2025-09-30 | $4.85B | $646.6M | +15.38% |
| Q2 2025 | 2025-06-30 | $4.57B | $556.4M | +13.88% |
| Q1 2025 | 2025-03-31 | $4.21B | $389.4M | +10.18% |
| Q4 2024 | 2024-12-31 | $4.24B | $410.1M | +10.71% |
| Q3 2024 | 2024-09-30 | $4.21B | $366.0M | +9.53% |
| Q2 2024 | 2024-06-30 | $4.01B | $607.2M | +17.85% |
| Q1 2024 | 2024-03-31 | $3.82B | $432.4M | +12.75% |
| Q4 2023 | 2023-12-31 | $3.83B | $283.5M | +7.99% |
| Q3 2023 | 2023-09-30 | $3.84B | $303.8M | +8.59% |
| Q2 2023 | 2023-06-30 | $3.40B | $72.0M | +2.16% |
| Q1 2023 | 2023-03-31 | $3.39B | −$41.6M | −1.21% |
| Q4 2022 | 2022-12-31 | $3.55B | −$96.9M | −2.66% |
| Q3 2022 | 2022-09-30 | $3.54B | $62.9M | +1.81% |
| Q2 2022 | 2022-06-30 | $3.33B | −$179.0M | −5.10% |
| Q1 2022 | 2022-03-31 | $3.43B | $178.3M | +5.48% |
| Q4 2021 | 2021-12-31 | $3.64B | $236.2M | +6.93% |
| Q3 2021 | 2021-09-30 | $3.47B | $165.0M | +4.99% |
| Q2 2021 | 2021-06-30 | $3.51B | $135.1M | +4.00% |
| Q1 2021 | 2021-03-31 | $3.26B | $975.6M | +42.80% |
| Q4 2020 | 2020-12-31 | $3.41B | $1.01B | +42.25% |
| Q3 2020 | 2020-09-30 | $3.31B | $765.7M | +30.12% |
| Q2 2020 | 2020-06-30 | $3.37B | $658.0M | +24.22% |
| Q1 2020 | 2020-03-31 | $2.28B | $265.6M | +13.19% |
| Q4 2019 | 2019-12-31 | $2.40B | $820.3M | +52.09% |
| Q3 2019 | 2019-09-30 | $2.54B | $866.0M | +51.68% |
| Q2 2019 | 2019-06-30 | $2.72B | $927.0M | +51.81% |
| Q1 2019 | 2019-03-31 | $2.01B | $90.9M | +4.72% |
| Q4 2018 | 2018-12-31 | $1.57B | −$419.9M | −21.05% |
| Q3 2018 | 2018-09-30 | $1.68B | $317.4M | +23.37% |
| Q2 2018 | 2018-06-30 | $1.79B | $355.1M | +24.76% |
| Q1 2018 | 2018-03-31 | $1.92B | $789.2M | +69.60% |
| Q4 2017 | 2017-12-31 | $1.99B | $731.9M | +57.96% |
| Q3 2017 | 2017-09-30 | $1.36B | $45.4M | +3.46% |
| Q2 2017 | 2017-06-30 | $1.43B | $52.1M | +3.77% |
| Q1 2017 | 2017-03-31 | $1.13B | −$183.0M | −13.90% |
| Q4 2016 | 2016-12-31 | $1.26B | −$123.7M | −8.92% |
| Q3 2016 | 2016-09-30 | $1.31B | −$123.2M | −8.58% |
| Q2 2016 | 2016-06-30 | $1.38B | −$148.6M | −9.71% |
| Q1 2016 | 2016-03-31 | $1.32B | −$311.8M | −19.15% |
| Q4 2015 | 2015-12-31 | $1.39B | $306.9M | +28.43% |
| Q3 2015 | 2015-09-30 | $1.44B | $449.8M | +45.60% |
| Q2 2015 | 2015-06-30 | $1.53B | $498.1M | +48.24% |
| Q1 2015 | 2015-03-31 | $1.63B | $548.5M | +50.77% |
| Q4 2014 | 2014-12-31 | $1.08B | $659.1M | +156.72% |
| Q3 2014 | 2014-09-30 | $986.4M | $538.9M | +120.41% |
| Q2 2014 | 2014-06-30 | $1.03B | $570.1M | +123.25% |
| Q1 2014 | 2014-03-31 | $1.08B | $608.7M | +129.08% |
| Q4 2013 | 2013-12-31 | $420.5M | $133.0M | +46.26% |
| Q3 2013 | 2013-09-30 | $447.5M | $125.2M | +38.82% |
| Q2 2013 | 2013-06-30 | $462.6M | $144.1M | +45.24% |
| Q1 2013 | 2013-03-31 | $471.6M | $131.3M | +38.58% |
| Q4 2012 | 2012-12-31 | $287.5M | $5.6M | +1.99% |
| Q3 2012 | 2012-09-30 | $322.4M | $12.1M | +3.91% |
| Q2 2012 | 2012-06-30 | $318.5M | −$22.4M | −6.56% |
| Q1 2012 | 2012-03-31 | $340.3M | −$28.8M | −7.79% |
| Q4 2011 | 2011-12-31 | $281.9M | −$111.3M | −28.31% |
| Q3 2011 | 2011-09-30 | $310.2M | −$102.4M | −24.81% |
| Q2 2011 | 2011-06-30 | $340.8M | −$99.4M | −22.57% |
| Q1 2011 | 2011-03-31 | $369.1M | — | — |
| Q4 2010 | 2010-12-31 | $393.3M | −$88.1M | −18.31% |
| Q3 2010 | 2010-09-30 | $412.6M | — | — |
| Q2 2010 | 2010-06-30 | $440.2M | — | — |
| Q4 2009 | 2009-12-31 | $481.4M | — | — |
Alnylam Pharmaceuticals total assets trends
Over the last five fiscal years, Alnylam Pharmaceuticals's total assets increased from $3.41B to $4.97B, a change of $1.56B. The latest reported quarter, Q2 2026, shows $5.56B.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alnylam Pharmaceuticals source filings ↗